Unknown

Dataset Information

0

A bimolecular modification strategy for developing long-lasting bone anabolic aptamer.


ABSTRACT: The molecular weight of nucleic acid aptamers (20 kDa) is lower than the cutoff threshold of the renal filtration (30-50 kDa), resulting in a very short half-life, which dramatically limits their druggability. To address this, we utilized 3-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)-N-(4-hydroxy-2-oxo-2H-chromen-6-yl)propenamide (HC) and 12-((2,5-dioxopyrrolidin-1-yl)oxy)-12-oxododecanoic acid (DA), two newly designed coupling agents, for synergistic binding to human serum albumin (HSA). Both HC and DA are conjugated to a bone anabolic aptamer (Apc001) against sclerostin to form an Apc001OC conjugate with high binding affinity to HSA. Notably, HC and DA could synergistically facilitate prolonging the half-life of the conjugated Apc001 and promoting its bone anabolic potential. Using the designed blocking peptides, the mechanism studies indicate that the synergistic effect of HC-DA on pharmacokinetics and bone anabolic potential of the conjugated Apc001 is achieved via their synergistic binding to HSA. Moreover, biweekly Apc001OC at 50 mg/kg shows comparable bone anabolic potential to the marketed sclerostin antibody given weekly at 25 mg/kg. This proposed bimolecular modification strategy could help address the druggability challenge for aptamers with a short half-life.

SUBMITTER: Zhang H 

PROVIDER: S-EPMC10709176 | biostudies-literature | 2023 Dec

REPOSITORIES: biostudies-literature

altmetric image

Publications

A bimolecular modification strategy for developing long-lasting bone anabolic aptamer.

Zhang Huarui H   Yu Sifan S   Ni Shuaijian S   Gubu Amu A   Ma Yuan Y   Zhang Yihao Y   Li Haitian H   Wang Yuzhe Y   Wang Luyao L   Zhang Zongkang Z   Yu Yuanyuan Y   Lyu Aiping A   Zhang Baoting B   Zhang Ge G  

Molecular therapy. Nucleic acids 20231110


The molecular weight of nucleic acid aptamers (20 kDa) is lower than the cutoff threshold of the renal filtration (30-50 kDa), resulting in a very short half-life, which dramatically limits their druggability. To address this, we utilized 3-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)-N-(4-hydroxy-2-oxo-2H-chromen-6-yl)propenamide (HC) and 12-((2,5-dioxopyrrolidin-1-yl)oxy)-12-oxododecanoic acid (DA), two newly designed coupling agents, for synergistic binding to human serum albumin (HSA). Both HC and  ...[more]

Similar Datasets

| S-EPMC5508976 | biostudies-literature
| S-EPMC8999942 | biostudies-literature
| S-EPMC6794936 | biostudies-literature
| S-EPMC6509425 | biostudies-literature
| S-EPMC2678458 | biostudies-literature
| S-EPMC6254543 | biostudies-literature
| S-EPMC2343592 | biostudies-literature
| S-EPMC10976566 | biostudies-literature
| S-EPMC4884960 | biostudies-literature
2014-06-17 | E-GEOD-50677 | biostudies-arrayexpress